BR9909791A - Treatment of anxiety disorders in general with partoxetine - Google Patents

Treatment of anxiety disorders in general with partoxetine

Info

Publication number
BR9909791A
BR9909791A BR9909791-5A BR9909791A BR9909791A BR 9909791 A BR9909791 A BR 9909791A BR 9909791 A BR9909791 A BR 9909791A BR 9909791 A BR9909791 A BR 9909791A
Authority
BR
Brazil
Prior art keywords
treatment
general
partoxetine
anxiety disorders
human
Prior art date
Application number
BR9909791-5A
Other languages
Portuguese (pt)
Inventor
Rocco Zaninelli
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9909791A publication Critical patent/BR9909791A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Abstract

"TRATAMENTO DE DISTúRBIOS DE ANSIEDADE DE MODO GERAL COM A PARTOXETINA" Um método para o tratamento do distúrbio da ansiedade de modo geral, cujo método compreende a administração de uma quantidade efetiva, não-tóxica de paroxetina ou um sal ou solvato farmaceuticamente aceitável dela proveniente, a um animal humano ou não-humano com necessidade disto."TREATMENT OF ANXIETY DISORDERS IN A GENERAL MODE WITH PARTOXETINE" A method for the treatment of anxiety disorder in general, the method of which involves administering an effective, non-toxic amount of paroxetine or a pharmaceutically acceptable salt or solvate from it , to a human or non-human animal in need of this.

BR9909791-5A 1998-04-22 1999-04-22 Treatment of anxiety disorders in general with partoxetine BR9909791A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
PCT/US1999/008786 WO1999053919A1 (en) 1998-04-22 1999-04-22 Treatment of generalized anxiety disorder with paroxetine

Publications (1)

Publication Number Publication Date
BR9909791A true BR9909791A (en) 2000-12-26

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909791-5A BR9909791A (en) 1998-04-22 1999-04-22 Treatment of anxiety disorders in general with partoxetine

Country Status (20)

Country Link
EP (1) EP1073437A4 (en)
JP (1) JP2002512189A (en)
KR (1) KR20010034817A (en)
CN (1) CN1298301A (en)
AP (1) AP2000001959A0 (en)
AU (1) AU3864899A (en)
BG (1) BG104939A (en)
BR (1) BR9909791A (en)
CA (1) CA2328896A1 (en)
CZ (1) CZ20003885A3 (en)
EA (1) EA200001088A1 (en)
GB (1) GB9808479D0 (en)
HU (1) HUP0101350A3 (en)
ID (1) ID27546A (en)
IL (1) IL139167A0 (en)
NO (1) NO20005286L (en)
PL (1) PL343494A1 (en)
SK (1) SK15672000A3 (en)
TR (1) TR200003082T2 (en)
WO (1) WO1999053919A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
EA200001088A1 (en) 2001-04-23
EP1073437A4 (en) 2003-04-16
TR200003082T2 (en) 2001-01-22
CZ20003885A3 (en) 2001-09-12
IL139167A0 (en) 2001-11-25
SK15672000A3 (en) 2001-04-09
PL343494A1 (en) 2001-08-27
NO20005286D0 (en) 2000-10-20
NO20005286L (en) 2000-12-20
ID27546A (en) 2001-04-12
HUP0101350A2 (en) 2002-05-29
HUP0101350A3 (en) 2002-06-28
AU3864899A (en) 1999-11-08
AP2000001959A0 (en) 2000-12-31
GB9808479D0 (en) 1998-06-17
JP2002512189A (en) 2002-04-23
EP1073437A1 (en) 2001-02-07
CN1298301A (en) 2001-06-06
KR20010034817A (en) 2001-04-25
CA2328896A1 (en) 1999-10-28
BG104939A (en) 2001-09-28
WO1999053919A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
EP1390491A4 (en) Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
FR13C0062I2 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR TREATING NEUROLOGICAL DISORDERS
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ES2166111T3 (en) USE OF TIAGABINE FOR THE TREATMENT OF SLEEP DISORDERS.
BR9602485A (en) Method for the treatment of Parkinson's disease pharmaceutical composition first pharmaceutical composition and method for obtaining antiParkinson effect
BE2012C005I2 (en)
BR0009776A (en) Treatment method
MXPA04001187A (en) Interleukin-1 receptors in the treatment of diseases.
BR9814923A (en) Method for treating alzheimer's disease
DE3786893D1 (en) PIPERIDE DERIVATIVE FOR THE TREATMENT OF PAIN.
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
BR9914631A (en) Tolerance-inducing oral immunological composition for disease prevention and / or treatment and method for disease prevention and / or treatment
DK0998287T3 (en) Use of levobupivacaine
DK0501705T3 (en) Use of tomoxetine for the treatment of diseases of the lower urinary tract
NO994165L (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, travel sickness and dizziness
EA200001010A1 (en) APPLICATION OF DEXMEDETOMIDINE FOR SEDATIVE IMPACT IN THE DEPARTMENT OF INTENSIVE THERAPY
BRPI0416882A (en) compound, pharmaceutical composition, method of treating a disorder, and use of a compound
IT1269185B (en) ASSOCIATION WITH A SYNERGIC EFFECT THAT HAS AN ANTAGONIST EFFECT OF THE RECEPTORS NK1 AND NK2
DK0636027T3 (en) Angiotensin II Antogonists for Disorders Associated with Impaired Neuronal Conduction Rate, especially Diabetic Neuropathy
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
BRPI0508053A (en) method of combating toxicity caused by an antifolate compound, and of treating a disease, uses enzyme having carboxy-peptidase g activity, antifolate compound, folate route rescue agent, and enzyme having carboxide activity. peptidase g and a folate route rescue agent, therapeutic system, and ex vivo method of cleaving a terminal 1-glutamate group of a compound, determining the rate and / or extent of cleavage of a compound, and cleavage of a compound
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
BR9814867A (en) Method for treating disease-related or drug-induced dyskinesias
BR9909791A (en) Treatment of anxiety disorders in general with partoxetine
BR0113646A (en) Treatment of inflammatory disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1917 DE 02/10/2007.